Literature DB >> 33401925

LncRNA PCAT7 promotes the malignant progression of breast cancer by regulating ErbB/PI3K/Akt pathway.

Jiaoqun Zhou1, Shiwei Zhang1, Mingyuan Luo1.   

Abstract

Aim: This study aimed to explore the mechanism of lncRNA PCAT7 underlying the progression of breast cancer, which will provide a basis for accurate diagnosis and targeted treatment.
Methods: Data from The Cancer Genome Atlas data associated with breast cancer were used to identify the target lncRNA. In vitro experiments were conducted to detect gene expression and the effect of the lncRNA on cancer cell activities.
Results: PCAT7 was found to be highly expressed in breast cancer tissue and cells, which activated the ErbB/PI3K/Akt pathway to potentiate cancer cell proliferation, migration and invasion and suppress apoptosis.
Conclusion: PCAT7 is likely to promote tumor cell activities by activating ErbB/PI3K/Akt pathway, in turn potentiating tumor malignant progression.

Entities:  

Keywords:  ErbB; PI3K; breast cancer; invasion; lncRNA PCAT7; proliferation

Year:  2021        PMID: 33401925     DOI: 10.2217/fon-2020-0273

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  Identification of CD4+ Conventional T Cells-Related lncRNA Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Breast Cancer.

Authors:  Shipeng Ning; Jianbin Wu; You Pan; Kun Qiao; Lei Li; Qinghua Huang
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

2.  High RRM2 expression has poor prognosis in specific types of breast cancer.

Authors:  Shen-Chao Shi; Yi Zhang; Tao Wang
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

3.  5-Methylcytosine-Related Long Noncoding RNAs Are Potential Biomarkers to Predict Overall Survival and Regulate Tumor-Immune Environment in Patients with Bladder Cancer.

Authors:  Zhuoyuan Li; Siyu Wang; Yuxian Chen; Yaozhou Huang; Tianping Li
Journal:  Dis Markers       Date:  2022-03-04       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.